{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T17:10:24Z","timestamp":1725210624707},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"DOI":"10.7759\/cureus.68392","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T16:46:41Z","timestamp":1725209201000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Personalized Add-On Ayurveda Therapy in Oxygen-Dependent Diabetic COVID-19 Patients: A 60-Day Study of Symptoms, Inflammation, and Radiological Changes"],"prefix":"10.7759","author":[{"given":"Somit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthikeyan","family":"Ramaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitravinda S","family":"Kakarla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith S","family":"Eranezhath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaithanya","family":"Chenthamarakshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Alagesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balagopal","family":"Satheesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indulal","family":"Unniappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Wilhalme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdis","family":"P\u012br\u0101gs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.04.049","article-title":"COVID-19 and diabetes mellitus: An unholy interaction of two pandemics","volume":"14","author":"Pal R","year":"2020","unstructured":"Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr. 2020, 14:513-7. 10.1016\/j.dsx.2020.04.049","journal-title":"Diabetes Metab Syndr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001343","article-title":"Clinical characteristics and outcomes of patients with severe covid-19 with diabetes","volume":"8","author":"Yan Y","year":"2020","unstructured":"Yan Y, Yang Y, Wang F, et al.. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. 2020, 8:10.1136\/bmjdrc-2020-001343","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3321","article-title":"Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics","volume":"36","author":"Maddaloni E","year":"2020","unstructured":"Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020, 36:e33213321. 10.1002\/dmrr.3321","journal-title":"Diabetes Metab Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta P","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395:1033-4. 10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06358-1","article-title":"Silent hypoxia in COVID-19: pathomechanism and possible management strategy","volume":"48","author":"Rahman A","year":"2021","unstructured":"Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep. 2021, 48:3863-9. 10.1007\/s11033-021-06358-1","journal-title":"Mol Biol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2020.1770685","article-title":"Biomarkers associated with COVID-19 disease progression","volume":"57","author":"Ponti G","year":"2020","unstructured":"Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020, 57:389-99. 10.1080\/10408363.2020.1770685","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms","volume":"12","author":"Proal AD","year":"2021","unstructured":"Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021, 12:698169. 10.3389\/fmicb.2021.698169","journal-title":"Front Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222888","article-title":"Longitudinal assessment of chest CT findings and pulmonary function after COVID-19 infection","volume":"307","author":"Han X","year":"2023","unstructured":"Han X, Chen L, Fan Y, et al.. Longitudinal assessment of chest CT findings and pulmonary function after COVID-19 infection. Radiology. 2023, 307:e222888. 10.1148\/radiol.222888","journal-title":"Radiology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.04.009","article-title":"Elevated troponin in patients with coronavirus disease 2019: possible mechanisms","volume":"26","author":"Tersalvi G","year":"2020","unstructured":"Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail. 2020, 26:470-5. 10.1016\/j.cardfail.2020.04.009","journal-title":"J Card Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100715","article-title":"The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study","volume":"32","author":"Perrone MA","year":"2021","unstructured":"Perrone MA, Spolaore F, Ammirabile M, Romeo F, Caciagli P, Ceriotti F, Bernardini S. The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study. Int J Cardiol Heart Vasc. 2021, 32:100715. 10.1016\/j.ijcha.2021.100715","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon CJ","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, G\u00f6tte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020, 295:6785-97. 10.1074\/jbc.RA120.013679","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers AJ","year":"2020","unstructured":"Pruijssers AJ, George AS, Sch\u00e4fer A, et al.. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020, 32:107940. 10.1016\/j.celrep.2020.107940","journal-title":"Cell Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1856655","article-title":"Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications","volume":"14","author":"Charan J","year":"2021","unstructured":"Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol. 2021, 14:95-103. 10.1080\/17512433.2021.1856655","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2022.109022","article-title":"The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis","volume":"183","author":"Hong S","year":"2022","unstructured":"Hong S, Wang H, Zhang Z, Qiao L. The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis. Steroids. 2022, 183:109022. 10.1016\/j.steroids.2022.109022","journal-title":"Steroids"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00510-X","article-title":"Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"401","year":"2023","unstructured":"Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY). a randomised, controlled, open-label, platform trial. Lancet. 2023, 401:1499-507. 10.1016\/S0140-6736(23)00510-X","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100694","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu J","year":"2023","unstructured":"Liu J, Pan X, Zhang S, et al.. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac. 2023, 33:100694. 10.1016\/j.lanwpc.2023.100694","journal-title":"Lancet Reg Health West Pac"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu X","year":"2020","unstructured":"Xu X, Han M, Li T, et al.. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020, 117:10970-5. 10.1073\/pnas.2005615117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY). a randomised, controlled, open-label, platform trial. Lancet. 2021, 397:1637-45. 10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01825-8","article-title":"Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis","volume":"51","author":"Deng J","year":"2023","unstructured":"Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infection. 2023, 51:21-35. 10.1007\/s15010-022-01825-8","journal-title":"Infection"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282688","article-title":"Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial","volume":"18","author":"Chopra A","year":"2023","unstructured":"Chopra A, Tillu G, Chuadhary K, et al.. Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial. PLoS One. 2023, 18:e0282688. 10.1371\/journal.pone.0282688","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2020.05.011","article-title":"Ayurvedic clinical profile of COVID-19 - A preliminary report","volume":"13","author":"Puthiyedath R","year":"2022","unstructured":"Puthiyedath R, Kataria S, Payyappallimana U, et al.. Ayurvedic clinical profile of COVID-19 - A preliminary report. J Ayurveda Integr Med. 2022, 13:100326. 10.1016\/j.jaim.2020.05.011","journal-title":"J Ayurveda Integr Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2022.102824","article-title":"A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India","volume":"67","author":"Sankhe AP","year":"2022","unstructured":"Sankhe AP, Memane NS, Gawali VP, et al.. A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India. Complement Ther Med. 2022, 67:102824. 10.1016\/j.ctim.2022.102824","journal-title":"Complement Ther Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2020.10.008","article-title":"A prospective clinical study of an Ayurveda regimen in COVID 19 patients","volume":"13","author":"Wanjarkhedkar P","year":"2022","unstructured":"Wanjarkhedkar P, Sarade G, Purandare B, Kelkar D. A prospective clinical study of an Ayurveda regimen in COVID 19 patients. J Ayurveda Integr Med. 2022, 13:100365. 10.1016\/j.jaim.2020.10.008","journal-title":"J Ayurveda Integr Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2022.100660","article-title":"Ayurvedic management through telemedicine of covid hypoxia non-dependent of oxygen support in a patient with chest CT score of 18\/25- A case report","volume":"13","author":"A S","year":"2022","unstructured":"A S, G M. Ayurvedic management through telemedicine of covid hypoxia non-dependent of oxygen support in a patient with chest CT score of 18\/25- A case report. J Ayurveda Integr Med. 2022, 13:100660. 10.1016\/j.jaim.2022.100660","journal-title":"J Ayurveda Integr Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2021.06.006","article-title":"Standalone Ayurvedic treatment of high-risk COVID-19 patients with multiple co-morbidities: A case series","volume":"13","author":"Girija PL","year":"2022","unstructured":"Girija PL, Sivan N, Naik P, Murugavel YA, M Ravindranath T, Cv K. Standalone Ayurvedic treatment of high-risk COVID-19 patients with multiple co-morbidities: A case series. J Ayurveda Integr Med. 2022, 13:100466. 10.1016\/j.jaim.2021.06.006","journal-title":"J Ayurveda Integr Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2021.08.002","article-title":"Ayurvedic management of persistent hypoxia in a diabetic and hypertensive COVID-19 patient in the post-hospitalization period-A case report","volume":"13","author":"Joshi J","year":"2022","unstructured":"Joshi J, Naranappa Salethoor S, Kulangara S, Edamala Narayanan PN, Puthiyedath R. Ayurvedic management of persistent hypoxia in a diabetic and hypertensive COVID-19 patient in the post-hospitalization period-A case report. J Ayurveda Integr Med. 2022, 13:100509. 10.1016\/j.jaim.2021.08.002","journal-title":"J Ayurveda Integr Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02624-1","article-title":"The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19\/SARS-CoV-2 with multiple comorbidities: a case report","volume":"15","author":"Mishra A","year":"2021","unstructured":"Mishra A, Bentur SA, Thakral S, Garg R, Duggal B. The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19\/SARS-CoV-2 with multiple comorbidities: a case report. J Med Case Rep. 2021, 15:95. 10.1186\/s13256-020-02624-1","journal-title":"J Med Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_495_21","article-title":"Multimodal ayurvedic approach in the management of moderate SARS-COV2 infection with co-morbidities - A case report","volume":"11","author":"Mythri HS","year":"2022","unstructured":"Mythri HS, Mahto RR. Multimodal ayurvedic approach in the management of moderate SARS-COV2 infection with co-morbidities - A case report. J Family Med Prim Care. 2022, 11:344-9. 10.4103\/jfmpc.jfmpc_495_21","journal-title":"J Family Med Prim Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/joa.joa_103_20","article-title":"Ayurvedic management of COVID-19\/SARS-CoV-2 along with chronic diabetes mellitus: A case study","volume":"15","author":"Nesari T","year":"2021","unstructured":"Nesari T, Galib R, Dharmarajan P, et al.. Ayurvedic management of COVID-19\/SARS-CoV-2 along with chronic diabetes mellitus: A case study. J Ayurveda. 2021, 15:311. 10.4103\/joa.joa_103_20","journal-title":"J Ayurveda"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2021.03.002","article-title":"A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only ayurvedic medicines","volume":"13","author":"Patil S","year":"2022","unstructured":"Patil S. A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only ayurvedic medicines. J Ayurveda Integr Med. 2022, 13:100420. 10.1016\/j.jaim.2021.03.002","journal-title":"J Ayurveda Integr Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hermed.2023.100836","article-title":"A prospective, controlled, pilot study of personalised add-on ayurveda treatment in high-risk type II diabetes COVID-19 patients","volume":"43","author":"Kumar S","year":"2024","unstructured":"Kumar S, Eranezhath SS, Vishwanathan VK, et al.. A prospective, controlled, pilot study of personalised add-on ayurveda treatment in high-risk type II diabetes COVID-19 patients. Jr Her Med. 2024, 43:100836. 10.1016\/j.hermed.2023.100836","journal-title":"Jr Her Med"},{"key":"ref34","unstructured":"ICMR. Clinical guidance for management of adult covid-19 patients. (2021). https:\/\/www.icmr.gov.in\/pdf\/covid\/techdoc\/COVID_Clinical_Management_19032023.pdf."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2020.11.010","article-title":"Pathophysiology of Covid-19 and host centric approaches in Ayurveda","volume":"13","author":"Pandkar PD","year":"2022","unstructured":"Pandkar PD, Sachdeva V. Pathophysiology of Covid-19 and host centric approaches in Ayurveda. J Ayurveda Integr Med. 2022, 13:100380. 10.1016\/j.jaim.2020.11.010","journal-title":"J Ayurveda Integr Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1852119","article-title":"Evaluation of traditional ayurvedic Kadha for prevention and management of the novel Coronavirus (SARS-CoV-2) using in silico approach","volume":"40","author":"Maurya DK","year":"2022","unstructured":"Maurya DK, Sharma D. Evaluation of traditional ayurvedic Kadha for prevention and management of the novel Coronavirus (SARS-CoV-2) using in silico approach. J Biomol Struct Dyn. 2022, 40:3949-64. 10.1080\/07391102.2020.1852119","journal-title":"J Biomol Struct Dyn"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1810778","article-title":"Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study","volume":"40","author":"Shree P","year":"2022","unstructured":"Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, Tripathi YB. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study. J Biomol Struct Dyn. 2022, 40:190-203. 10.1080\/07391102.2020.1810778","journal-title":"J Biomol Struct Dyn"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680134","article-title":"Neutrophils and COVID-19: Active participants and rational therapeutic targets","volume":"12","author":"Hazeldine J","year":"2021","unstructured":"Hazeldine J, Lord JM. Neutrophils and COVID-19: Active participants and rational therapeutic targets. Front Immunol. 2021, 12:680134. 10.3389\/fimmu.2021.680134","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652470","article-title":"Neutrophils in COVID-19","volume":"12","author":"Reusch N","year":"2021","unstructured":"Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Ba\u00dfler K, Schultze JL, Aschenbrenner AC. Neutrophils in COVID-19. Front Immunol. 2021, 12:652470. 10.3389\/fimmu.2021.652470","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.09.001","article-title":"Understanding the role of neutrophils in acute respiratory distress syndrome","volume":"44","author":"Yang SC","year":"2021","unstructured":"Yang SC, Tsai YF, Pan YL, Hwang TL. Understanding the role of neutrophils in acute respiratory distress syndrome. Biomed J. 2021, 44:439-46. 10.1016\/j.bj.2020.09.001","journal-title":"Biomed J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2021.03.006","article-title":"Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection","volume":"13","author":"Joshi MB","year":"2022","unstructured":"Joshi MB, Kamath A, Nair AS, Yedehali Thimmappa P, Sriranjini SJ, Gangadharan GG, Satyamoorthy K. Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection. J Ayurveda Integr Med. 2022, 13:100424. 10.1016\/j.jaim.2021.03.006","journal-title":"J Ayurveda Integr Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.13.1718","article-title":"Inflammation and thrombosis: the clot thickens","volume":"103","author":"Libby P","year":"2001","unstructured":"Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001, 103:1718-20. 10.1161\/01.cir.103.13.1718","journal-title":"Circulation"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: from pathophysiology to clinical management","volume":"17","author":"Lim S","year":"2021","unstructured":"Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021, 17:11-30. 10.1038\/s41574-020-00435-4","journal-title":"Nat Rev Endocrinol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107088","article-title":"Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients","volume":"89","author":"Valizadeh H","year":"2020","unstructured":"Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, et al.. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol. 2020, 89:107088. 10.1016\/j.intimp.2020.107088","journal-title":"Int Immunopharmacol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i3.10214","article-title":"Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study","volume":"91","author":"Soliman AT","year":"2020","unstructured":"Soliman AT, Prabhakaran Nair A, Al Masalamani MS, et al.. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Biomed. 2020, 91:e2020010. 10.23750\/abm.v91i3.10214","journal-title":"Acta Biomed"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.imr.2020.100489","article-title":"Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial","volume":"9","author":"Xiong WZ","year":"2020","unstructured":"Xiong WZ, Wang G, Du J, Ai W. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial. Integr Med Res. 2020, 9:100489. 10.1016\/j.imr.2020.100489","journal-title":"Integr Med Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950012","article-title":"Therapeutic effects of herbal-medicine combined therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chien TJ","year":"2022","unstructured":"Chien TJ, Liu CY, Chang YI, Fang CJ, Pai JH, Wu YX, Chen SW. Therapeutic effects of herbal-medicine combined therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022, 13:950012. 10.3389\/fphar.2022.950012","journal-title":"Front Pharmacol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013038","article-title":"Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes","volume":"12","author":"Alzaid F","year":"2020","unstructured":"Alzaid F, Julla JB, Diedisheim M, et al.. Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes. EMBO Mol Med. 2020, 12:e13038. 10.15252\/emmm.202013038","journal-title":"EMBO Mol Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12622","article-title":"Neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios: prognostic significance in COVID-19","volume":"13","author":"Bg S","year":"2021","unstructured":"Bg S, Gosavi S, Ananda Rao A, et al.. Neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios: prognostic significance in COVID-19. Cureus. 2021, 13:e12622. 10.7759\/cureus.12622","journal-title":"Cureus"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85760-y","article-title":"Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19","volume":"11","author":"Moin AS","year":"2021","unstructured":"Moin AS, Sathyapalan T, Diboun I, Atkin SL, Butler AE. Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19. Sci Rep. 2021, 11:6428. 10.1038\/s41598-021-85760-y","journal-title":"Sci Rep"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24188","article-title":"Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection","volume":"97","author":"Gatti A","year":"2020","unstructured":"Gatti A, Radrizzani D, Vigan\u00f2 P, Mazzone A, Brando B. Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection. Cytometry A. 2020, 97:887-90. 10.1002\/cyto.a.24188","journal-title":"Cytometry A"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.210215","article-title":"Can monocytopenia be a new indicator in determining survival in covid-19 disease?","volume":"67","author":"Pehlivan O","year":"2021","unstructured":"Pehlivan O, Serin SO, Yesil EE, Demirdag F. Can monocytopenia be a new indicator in determining survival in covid-19 disease?. Clin Lab. 2021, 67:10.7754\/Clin.Lab.2021.210215","journal-title":"Clin Lab"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s13596-013-0132-4","article-title":"In-vivo immunomodulatory activity of standardized Stereospermum suaveolens (Roxb.) DC. root extract","volume":"14","author":"Maji AK","year":"2014","unstructured":"Maji AK, Samanta SK, Mahapatra S, Banerji P, Banerjee D. In-vivo immunomodulatory activity of standardized Stereospermum suaveolens (Roxb.) DC. root extract. Orient Pharm Exp Med. 2014, 14:47-54. 10.1007\/s13596-013-0132-4","journal-title":"Orient Pharm Exp Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-16280-5","article-title":"Ayurveda Rasayana as antivirals and immunomodulators: potential applications in COVID-19","volume":"28","author":"Singh R","year":"2021","unstructured":"Singh R, Goel S, Bourgeade P, Aleya L, Tewari D. Ayurveda Rasayana as antivirals and immunomodulators: potential applications in COVID-19. Environ Sci Pollut Res Int. 2021, 28:55925-51. 10.1007\/s11356-021-16280-5","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99705-y","article-title":"Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals","volume":"11","author":"Rajamanickam A","year":"2021","unstructured":"Rajamanickam A, Kumar NP, Pandiarajan AN, et al.. Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. Sci Rep. 2021, 11:20254. 10.1038\/s41598-021-99705-y","journal-title":"Sci Rep"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04702-4","article-title":"Fc\u03b3R-mediated SARS-CoV-2 infection of monocytes activates inflammation","volume":"606","author":"Junqueira C","year":"2022","unstructured":"Junqueira C, Crespo \u00c2, Ranjbar S, et al.. Fc\u03b3R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022, 606:576-84. 10.1038\/s41586-022-04702-4","journal-title":"Nature"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1055\/a-1581-4355","article-title":"Platelets and COVID-19","volume":"41","author":"Rohlfing AK","year":"2021","unstructured":"Rohlfing AK, Rath D, Geisler T, Gawaz M. Platelets and COVID-19. Hamostaseologie. 2021, 41:379-85. 10.1055\/a-1581-4355","journal-title":"Hamostaseologie"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16817","article-title":"The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants","volume":"190","author":"Jiang SQ","year":"2020","unstructured":"Jiang SQ, Huang QF, Xie WM, Lv C, Quan XQ. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Br J Haematol. 2020, 190:e29-33. 10.1111\/bjh.16817","journal-title":"Br J Haematol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04019-0","article-title":"Mechanism of thrombocytopenia in COVID-19 patients","volume":"99","author":"Xu P","year":"2020","unstructured":"Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020, 99:1205-8. 10.1007\/s00277-020-04019-0","journal-title":"Ann Hematol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807934","article-title":"The COVID complex: a review of platelet activation and immune complexes in COVID-19","volume":"13","author":"Jevtic SD","year":"2022","unstructured":"Jevtic SD, Nazy I. The COVID complex: a review of platelet activation and immune complexes in COVID-19. Front Immunol. 2022, 13:807934. 10.3389\/fimmu.2022.807934","journal-title":"Front Immunol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25767","article-title":"Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19","volume":"92","author":"Qu R","year":"2020","unstructured":"Qu R, Ling Y, Zhang YH, et al.. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020, 92:1533-41. 10.1002\/jmv.25767","journal-title":"J Med Virol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1159\/000512007","article-title":"The impact of COVID-19 disease on platelets and coagulation","volume":"88","author":"Wool GD","year":"2021","unstructured":"Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021, 88:15-27. 10.1159\/000512007","journal-title":"Pathobiology"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2020.1768523","article-title":"Hemostatic laboratory derangements in COVID-19 with a focus on platelet count","volume":"31","author":"Amgalan A","year":"2020","unstructured":"Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets. 2020, 31:740-5. 10.1080\/09537104.2020.1768523","journal-title":"Platelets"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30854-0","article-title":"Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study","volume":"395","author":"Banerjee A","year":"2020","unstructured":"Banerjee A, Pasea L, Harris S, et al.. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet. 2020, 395:1715-25. 10.1016\/S0140-6736(20)30854-0","journal-title":"Lancet"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103892","article-title":"Persistent cardiac injury - An important component of long COVID-19 syndrome","volume":"77","author":"Chidambaram V","year":"2022","unstructured":"Chidambaram V, Kumar A, Calcaterra G, Mehta JL. Persistent cardiac injury - An important component of long COVID-19 syndrome. EBioMedicine. 2022, 77:103892. 10.1016\/j.ebiom.2022.103892","journal-title":"EBioMedicine"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020201473","article-title":"CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation","volume":"296","author":"Prokop M","year":"2020","unstructured":"Prokop M, van Everdingen W, van Rees Vellinga T, et al.. CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology. 2020, 296:E97-E104. 10.1148\/radiol.2020201473","journal-title":"Radiology"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203153","article-title":"Six-month follow-up chest CT findings after severe COVID-19 pneumonia","volume":"299","author":"Han X","year":"2021","unstructured":"Han X, Fan Y, Alwalid O, et al.. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021, 299:E177-86. 10.1148\/radiol.2021203153","journal-title":"Radiology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020200370","article-title":"Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)","volume":"295","author":"Pan F","year":"2020","unstructured":"Pan F, Ye T, Sun P, et al.. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020, 295:715-21. 10.1148\/radiol.2020200370","journal-title":"Radiology"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021211199","article-title":"Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19","volume":"302","author":"Pan F","year":"2022","unstructured":"Pan F, Yang L, Liang B, et al.. Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19. Radiology. 2022, 302:709-19. 10.1148\/radiol.2021211199","journal-title":"Radiology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/278776-evaluating-personalized-add-on-ayurveda-therapy-in-oxygen-dependent-diabetic-covid-19-patients-a-60-day-study-of-symptoms-inflammation-and-radiological-changes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T16:46:47Z","timestamp":1725209207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/278776-evaluating-personalized-add-on-ayurveda-therapy-in-oxygen-dependent-diabetic-covid-19-patients-a-60-day-study-of-symptoms-inflammation-and-radiological-changes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.68392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}